Gilad E Amiel
Overview
Explore the profile of Gilad E Amiel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
608
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Castel O, Alperin M, Ungar L, Kravtsov I, Amiel G, Karkabi K
J Cancer Educ
. 2010 Oct;
26(2):315-21.
PMID: 20972846
Clinicians often fail to adequately meet prostate cancer patients' information needs, and patients may receive different kinds of information from their doctors. This study aims to describe urologists' attitudes regarding...
22.
Isbarn H, Karakiewicz P, Shariat S, Capitanio U, Palapattu G, Sagalowsky A, et al.
J Urol
. 2009 Jun;
182(2):459-65.
PMID: 19524971
Purpose: We hypothesized that in patients with T2N0 stage disease at transurethral bladder tumor resection a lower residual cancer stage (P1N0 or less) at radical cystectomy may correlate with improved...
23.
24.
Sonpavde G, Amiel G, Mims M, Hayes T, Lerner S
Expert Opin Pharmacother
. 2008 Jul;
9(11):1885-93.
PMID: 18627327
Background: Occult micrometastasis at the time of radical cystectomy leads predominantly to distant failures in patients with locally advanced, muscle-invasive transitional cell carcinoma of the bladder. Objectives: Data supporting neoadjuvant...
25.
Walz J, Shariat S, Suardi N, Perrotte P, Lotan Y, Palapattu G, et al.
BJU Int
. 2008 May;
101(11):1356-61.
PMID: 18454792
Objective: To assess the effect of adjuvant chemotherapy (ACHT; methotrexate, vinblastine, adriamycin and cisplatin, MVAC, or gemcitabine/cisplatin, GC) on the rate of cancer-specific survival and overall survival, as the benefit...
26.
Castel O, Ungar L, Alperin M, Amiel G, Karkabi K
Support Care Cancer
. 2007 Nov;
16(8):955-61.
PMID: 18043950
Objectives: This study aimed to describe family physicians' perceptions regarding the concerns of men with prostate cancer as well as their beliefs and attitudes toward information sharing and decision making...
27.
Bastian P, Hutterer G, Shariat S, Rogers C, Palapattu G, Lotan Y, et al.
BJU Int
. 2007 Sep;
101(4):450-4.
PMID: 17850359
Objective: To examine whether the presence of microscopic (pT3a) or macroscopic (pT3b) disease worsens the prognosis relative to pT2 disease at radical cystectomy, as the prognostic significance of pT3a vs...
28.
Shariat S, Karakiewicz P, Palapattu G, Amiel G, Lotan Y, Rogers C, et al.
Clin Cancer Res
. 2006 Nov;
12(22):6663-76.
PMID: 17121885
Aims: To develop multivariate nomograms that determine the probabilities of all-cause and bladder cancer-specific survival after radical cystectomy and to compare their predictive accuracy to that of American Joint Committee...
29.
Nielsen M, Shariat S, Karakiewicz P, Lotan Y, Rogers C, Amiel G, et al.
Eur Urol
. 2006 Nov;
51(3):699-706.
PMID: 17113703
Objective: Bladder cancer (BCa) is a disease of older persons, the incidence of which is expected to increase as the population ages. There is controversy, however, regarding the outcomes of...
30.
Shariat S, Karakiewicz P, Palapattu G, Lotan Y, Rogers C, Amiel G, et al.
J Urol
. 2006 Nov;
176(6 Pt 1):2414-22.
PMID: 17085118
Purpose: We present the characteristics and outcomes of a large, contemporary, consecutive series of patients treated with radical cystectomy and pelvic lymphadenectomy for transitional cell carcinoma of the bladder. Materials...